ABOS (STOCKS)
Acumen Pharmaceuticals, Inc. Common Stock
$2.590000
+0.120000 (+4.86%)
Prev close: $2.470000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Daniel J. O'Connell
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $181.98M
- Employees
- 52
- P/E (TTM)
- -1.25
- P/B (TTM)
- 2.12
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.41 | $-0.46 | +0.0522 | +11.29% |
|
Sep 2025 (Q3)
|
$-0.44 | $-0.62 | +0.1757 | +28.54% |
|
Jun 2025 (Q2)
|
$-0.68 | $-0.55 | -0.1312 | -23.91% |
|
Mar 2025 (Q1)
|
$-0.48 | $-0.68 | +0.1966 | +29.06% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $2.50M |
| Operating Expenses | $123.83M |
| Research and Development | $104.89M |
| Other Operating Expenses | $18.95M |
| Operating Income/Loss | -$123.83M |
| Income/Loss From Continuing Operations After Tax | -$121.34M |
| Income/Loss From Continuing Operations Before Tax | -$121.34M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$121.34M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$121.34M |
| Net Income/Loss Available To Common Stockholders, Basic | -$121.34M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.00 |
| Diluted Earnings Per Share | -$2.00 |
| Basic Average Shares | 60,561,836 |
| Diluted Average Shares | 60,561,836 |
| Assets | $122.83M |
| Current Assets | $122.25M |
| Cash | $116.90M |
| Other Current Assets | $5.35M |
| Noncurrent Assets | $581.00K |
| Fixed Assets | $103.00K |
| Other Non-current Assets | $478.00K |
| Liabilities | $52.40M |
| Current Liabilities | $30.01M |
| Accounts Payable | $554.00K |
| Other Current Liabilities | $29.45M |
| Noncurrent Liabilities | $22.40M |
| Long-term Debt | $22.40M |
| Equity | $70.43M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $70.43M |
| Liabilities And Equity | $122.83M |
| Net Cash Flow From Operating Activities | -$115.54M |
| Net Cash Flow From Operating Activities, Continuing | -$115.54M |
| Net Cash Flow From Investing Activities | $133.93M |
| Net Cash Flow From Investing Activities, Continuing | $133.93M |
| Net Cash Flow From Financing Activities | -$34.00K |
| Net Cash Flow From Financing Activities, Continuing | -$34.00K |
| Net Cash Flow | $18.36M |
| Net Cash Flow, Continuing | $18.36M |
| Comprehensive Income/Loss | -$121.20M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$121.20M |
| Other Comprehensive Income/Loss | -$121.20M |